-
公开(公告)号：US4818764A
公开(公告)日：1989-04-04
申请号：US230195
申请日：1981-02-02
IPC分类号： C07D405/04 , A61K31/415 , A61K31/4178 , A61P3/08 , A61P7/10 , A61P9/06 , A61P9/12 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/24 , A61P25/26 , C07D319/20 , C07D407/06 , C07D403/00
CPC分类号： C07D319/20
摘要： 2-[2-(1,4-Benzodioxanyl)]-2-imidazoline or a non-toxic salt thereof, substantially free of 2-[2-(2-methyl-1,3-benzodioxyl)]- 2-imidazoline or a non-toxic salt thereof.2-[2-(1,4-Benzodioxanyl)]-2-imidazoline or a non-toxic salt thereof characterised in that the nuclear magnetic resonance spectrum of the compound in a protonated form exhibits multiplets in the region of .tau.4.4 and .tau.5.4.Process for the preparation of 2-[2-(1,4-benzodioxanyl)]-2-imidazoline, pharmaceutical compositions thereof or of its salts, and their use as presynaptic .alpha..sub.2 -adrenoreceptor antagonists.
摘要翻译： 2- [2-（1,4-苯并二恶烷基）] - 2-咪唑啉或其无毒盐，基本上不含2- [2-（2-甲基-1,3-苯并二恶基）] - 其无毒盐。 2- [2-（1,4-苯并二恶烷基）] - 2-咪唑啉或其无毒盐，其特征在于质子化形式的化合物的核磁共振谱在τ4.4和τ4.4的区域中显示多重峰 。 制备2- [2-（1,4-苯并二恶烷基）] - 2-咪唑啉的方法，其药物组合物或其盐，以及它们作为突触前α2-肾上腺素受体拮抗剂的用途。
-
公开(公告)号：US20060069113A1
公开(公告)日：2006-03-30
申请号：US11254525
申请日：2005-10-20
IPC分类号： A61K31/485 , A61K31/137
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
-
公开(公告)号：US20060058333A1
公开(公告)日：2006-03-16
申请号：US11254988
申请日：2005-10-20
IPC分类号： A61K31/485
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
-
公开(公告)号：US20060058332A1
公开(公告)日：2006-03-16
申请号：US11254602
申请日：2005-10-20
IPC分类号： A61K31/485
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
